CD38 and Miyoshi myopathy: Emerging evidence, based on both in vitro studies and clinical trials, suggests that VD supplementation may exert beneficial effects as an adjuvant treatment for MM patients, particularly in combination with novel chemotherapeutic agents such as lenalidomide, bortezomib, and anti-CD38 antibodies.